ARTICLE | Clinical News
FX125L: Phase I data
January 18, 2010 8:00 AM UTC
In a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase I trial in 36 healthy volunteers, 150, 500 and 1,500 mg doses of once-daily oral FX125L for 7 days were well tolerated with n...